口服依托泊苷延长给药用于铂类化疗后12个月内难治或复发的卵巢癌患者的II期研究。
Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy.
作者信息
de Wit R, van der Burg M E, van den Gaast A, Logmans A, Stoter G, Verweij J
机构信息
Department of Medical Oncology, Rotterdam Cancer Institute/Dr. Daniel den Hoed Kliniek, The Netherlands.
出版信息
Ann Oncol. 1994 Sep;5(7):656-7. doi: 10.1093/oxfordjournals.annonc.a058942.
PATIENTS AND METHODS
Twenty-eight patients with ovarian cancer refractory to or relapsing within 12 months after cisplatin-containing chemotherapy were treated with etoposide 50 mg/m2 daily for 21 days, followed by a 7-day break.
RESULTS
Of 25 evaluable patients, 4 achieved partial responses (16%, 95% confidence interval 5%-36%) of 4, 4, 7, and 10 months' duration. The platinum treatment-free intervals for these patients were 2, 9, 7, and 10 months, respectively. Etoposide in this schedule was generally well tolerated, with myelosuppression as the major toxicity, resulting in a median dose intensity over all cycles of 83% (range 47%-100%).
CONCLUSIONS
Prolonged oral etoposide is moderately active both in relapsed and platinum-refractory ovarian cancer, and a schedule of 50 mg/m2 days 1-21, every 4 weeks is fairly well tolerated in this usually heavily pretreated and elderly patient population.
患者与方法
28例对含顺铂化疗难治或在含顺铂化疗后12个月内复发的卵巢癌患者，接受依托泊苷50mg/m²每日给药，共21天，随后休息7天。
结果
25例可评估患者中，4例获得部分缓解（16%，95%置信区间5%-36%），缓解持续时间分别为4、4、7和10个月。这些患者的无铂治疗间期分别为2、9、7和10个月。该方案中的依托泊苷总体耐受性良好，主要毒性为骨髓抑制，所有周期的中位剂量强度为83%（范围47%-100%）。
结论
延长口服依托泊苷对复发和铂类难治性卵巢癌均有中度活性，对于通常经过多次治疗且年龄较大的患者群体，每4周1-21天50mg/m²的给药方案耐受性相当良好。
Zotero 插件